Jobbagy S, Chaudet KM, Gayhart M, Klepeis VE, Boland G, Tsao H, Duncan LM. Resilience of melanoma diagnostics at a tertiary-care hospital during the SARS-CoV-2 pandemic. JAAD Int. 2022 Aug 31. doi: 10.1016/j.jdin.2022.08.012. Epub ahead of print. PMID: 36061239; PMCID: PMC9428333.
Njauw CN, Ji Z, Pham DM, Simoneau A, Kumar R, Flaherty KT, Zou L, Tsao H. Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma. J Invest Dermatol. 2022 May;142(5):1413-1424.e6. doi: 10.1016/j.jid.2021.07.188. Epub 2021 Oct 21. PMID: 34687746.
Sanna A, Phung B, Mitra S, Lauss M, Choi J, Zhang T, Njauw CJ, Cordero E, Harbst K, Rosengren F, Cabrita R, Johansson I, Isaksson K, Ingvar C, Carneiro A, Brown K, Tsao H, Andersson M, Pietras K, Jönsson G. DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype. JCI Insight. 2022 Aug 30:e156577. doi: 10.1172/jci.insight.156577. Epub ahead of print. PMID: 36040798.
Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G; Melanoma Research Foundation. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 May 15;27(10):2678-2697. doi: 10.1158/1078-0432.CCR-20-4092. Epub 2021 Jan 7. PMID: 33414132; PMCID: PMC8127340.
Beaulieu D, Tsao H, Michaud DS, Okhovat JP, Halpern AC, Lundberg M, Geller AC. A geographically based cross-sectional analysis of SPOT me skin cancer screening data. J Am Acad Dermatol. 2021 Mar;84(3):809-810.e3. doi: 10.1016/j.jaad.2020.06.014. Epub 2020 Jun 10. PMID: 32534079.
Coroiu A, Moran C, Davine JA, Brophy K, Bergeron C, Tsao H, Körner A, Swetter SM, Geller AC. Patient-identified early clinical warning signs of nodular melanoma: a qualitative study. BMC Cancer. 2021 Apr 7;21(1):371. doi: 10.1186/s12885-021-08072-4. PMID: 33827477; PMCID: PMC8028760.
Guhan S, Boland G, Tanabe K, Lin W, Reddy B, Hawryluk EB, Sober AJ, Tsao H. Surgical delay and mortality for primary cutaneous melanoma. J Am Acad Dermatol. 2021 Apr;84(4):1089-1091. doi: 10.1016/j.jaad.2020.07.078. Epub 2020 Jul 22. PMID: 32711092; PMCID: PMC7375294.
Guhan SM, Shaughnessy M, Rajadurai A, Taylor M, Kumar R, Ji Z, Rashid S, Flaherty K, Tsao H. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. J Invest Dermatol. 2021 Mar 18:S0022-202X(21)00977-5. doi: 10.1016/j.jid.2020.12.035. Epub ahead of print. PMID: 33745909.
Ji Z, Njauw CN, Guhan S, Kumar R, Reddy B, Rajadurai A, Flaherty K, Tsao H. Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. J Invest Dermatol. 2021 May;141(5):1317-1324.e1. doi: 10.1016/j.jid.2020.06.041. Epub 2020 Nov 4. PMID: 33159968.
Njauw CN, Ji Z, Pham DM, Simoneau A, Kumar R, Flaherty KT, Zou L, Tsao H. Oncogenic KIT Induces Replication stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma. J Invest Dermatol. 2021 Oct 20:S0022-202X(21)02347-2. doi: 10.1016/j.jid.2021.07.188. Epub ahead of print. PMID: 34687746.
Rashid S, Tsao H. Effect of the COVID-19 Pandemic on Delayed Skin Cancer Services. Dermatol Clin. 2021 Oct;39(4):627-637. doi: 10.1016/j.det.2021.05.015. Epub 2021 May 28. PMID: 34556252; PMCID: PMC8162820.
Rashid S, Tsao H. Recognition, Staging, and Management of Melanoma. Med Clin North Am. 2021 Jul;105(4):643-661. doi: 10.1016/j.mcna.2021.04.005. PMID: 34059243.
Beaulieu D, Tsao H, Michaud DS, Okhovat JP, Halpern AC, Geller AC. Number needed to screen for presumptive screening diagnoses among first-time SPOTme screening participants (1992-2010). J Am Acad Dermatol. 2020 Jan;82(1):233-234. No abstract available.
Shaughnessy M, Njauw CN, Artomov M, Tsao H. Classifying Melanoma by TERT Promoter Mutational Status. J Invest Dermatol. 2020 Feb;140(2):390-394.e1. PMCID: PMC6983338 [Available on 2021-02-01]
Artomov M, Joseph V, Tiao G, Thomas T, Schrader K, Klein RJ, Kiezun A, Gupta N, Margolin L, Stratigos AJ, Kim I, Shannon K, Ellisen LW, Haber D, Getz G, Tsao H, Lipkin SM, Altshuler D, Offit K, Daly MJ. Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes. Eur J Hum Genet. 2019 May;27(5):824-828. PMCID: PMC6461796 [Available on 2020-05-01]
Klebanov N, Gunasekera NS, Lin WM, Hawryluk EB, Miller DM, Reddy BY, Christman MP, Beaulieu D, Rajadurai S, Duncan LM, Sober AJ, Tsao H. Clinical spectrum of cutaneous melanoma morphology. J Am Acad Dermatol. 2019 Jan;80(1):178-188.e3. PMCID: PMC6492030
Klebanov N, Artomov M, Goggins WB, Daly E, Daly MJ, Tsao H. Burden of unique and low prevalence somatic mutations correlates with cancer survival. Sci Rep. 2019 Mar 19;9(1):4848. PMCID: PMC6425006
Klebanov N, Lin WM, Artomov M, Shaughnessy M, Njauw CN, Bloom R, Eterovic AK, Chen K, Kim TB, Tsao SS, Tsao H. Use of Targeted Next-Generation Sequencing to Identify Activating Hot Spot Mutations in Cherry Angiomas. JAMA Dermatol. 2019 Feb 1;155(2):211-215. PMCID: PMC6440195
Kumar R, Njauw CN, Reddy BY, Ji Z, Rajadurai A, Klebanov N, Tsao H. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma. Oncogene. 2019 May;38(18):3504-3520. PMCID: PMC6756020
Phung B, Cieśla M, Sanna A, Guzzi N, Beneventi G, Cao Thi Ngoc P, Lauss M, Cabrita R, Cordero E, Bosch A, Rosengren F, Häkkinen J, Griewank K, Paschen A, Harbst K, Olsson H, Ingvar C, Carneiro A, Tsao H, Schadendorf D, Pietras K, Bellodi C, Jönsson G. The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. Cell Rep. 2019 Jun 18;27(12):3573-3586.e7.
Shaughnessy M, Lamuraglia G, Klebanov N, Ji Z, Rajadurai A, Kumar R, Flaherty K, Tsao H. Selective uveal melanoma inhibition with calcium channel blockade. Int J Oncol. 2019 Nov;55(5):1090-1096. PMCID: PMC6776194
Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019 Jan;80(1):208-250.
Work Group, Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019 Jan;80(1):208-250.
Zhang AJ, Rush PS, Tsao H, Duncan LM. BRCA1-associated protein (BAP1)-inactivated melanocytic tumors. J Cutan Pathol. 2019 Dec;46(12):965-972.
Bartenstein DW, Kelleher CM, Friedmann AM, Duncan LM, Tsao H, Sober AJ, Hawryluk EB. Contrasting features of childhood and adolescent melanomas. Pediatr Dermatol. 2018 May;35(3):354-360. PMCID: PMC6476315
Beaulieu D, Tsao H, Michaud DS, Okhovat JP, Halpern AC, Geller AC. Factors associated with suspected nonmelanoma skin cancers, dysplastic nevus, and cutaneous melanoma among first-time SPOTme screening program participants (2009-2010). J Am Acad Dermatol. 2018 Dec 10. [Epub ahead of print]
Eliades P, Abraham BJ, Ji Z, Miller DM, Christensen CL, Kwiatkowski N, Kumar R, Njauw CN, Taylor M, Miao B, Zhang T, Wong KK, Gray NS, Young RA, Tsao H. High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma. J Invest Dermatol. 2018 Jul;138(7):1582-1590. PMCID: PMC6019629
Karagianni F, Njauw CN, Kypreou KP, Stergiopoulou A, Plaka M, Polydorou D, Chasapi V, Pappas L, Stratigos I, Champsas G, Panagiotou P, Gogas H, Evangelou E, Tsao H, Stratigos A, Stefanaki I. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters. Acta Derm Venereol. 2018 Oct 10;98(9):862-866. PMCID: PMC6572781
Klebanov N, Gunasekera NS, Lin WM, Hawryluk EB, Miller DM, Reddy BY, Christman MP, Beaulieu D, Rajadurai S, Duncan LM, Sober AJ, Tsao H. Clinical spectrum of cutaneous melanoma morphology. J Am Acad Dermatol. 2018 Aug 28. pii: S0190-9622(18)32482-4. [Epub ahead of print]
Klebanov N, Reddy BY, Husain S, Silvers DN, Grossman ME, Tsao H. Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation. Am J Dermatopathol. 2018 May;40(5):378-382. PMCID: PMC6426128
Okhovat JP, Beaulieu D, Tsao H, Halpern AC, Michaud DS, Shaykevich S, Geller AC. The first 30 years of the American Academy of Dermatology skin cancer screening program: 1985-2014. J Am Acad Dermatol. 2018 Nov;79(5):884-891.e3. PMCID: PMC6454210
Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, de la Fouchardière A, Cabaret O, Golmard L, Stoppa-Lyonnet D, Garfield E, Njauw CN, Cheung M, Turunen JA, Repo P, Järvinen RS, van Doorn R, Jager MJ, Luyten GPM, Marinkovic M, Chau C, Potrony M, Höiom V, Helgadottir H, Pastorino L, Bruno W, Andreotti V, Dalmasso B, Ciccarese G, Queirolo P, Mastracci L, Wadt K, Kiilgaard JF, Speicher MR, van Poppelen N, Kilic E, Al-Jamal RT, Dianzani I, Betti M, Bergmann C, Santagata S, Dahiya S, Taibjee S, Burke J, Poplawski N, O'Shea SJ, Newton-Bishop J, Adlard J, Adams DJ, Lane AM, Kim I, Klebe S, Racher H, Harbour JW, Nickerson ML, Murali R, Palmer JM, Howlie M, Symmons J, Hamilton H, Warrier S, Glasson W, Johansson P, Robles-Espinoza CD, Ossio R, de Klein A, Puig S, Ghiorzo P, Nielsen M, Kivelä TT, Tsao H, Testa JR, Gerami P, Stern MH, Paillerets BB, Abdel-Rahman MH, Hayward NK. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst. 2018 Dec 1;110(12):1328-1341. PMCID: PMC6292796
Artomov M, Stratigos AJ, Kim I, Kumar R, Lauss M, Reddy BY, Miao B, Daniela Robles-Espinoza C, Sankar A, Njauw CN, Shannon K, Gragoudas ES, Marie Lane A, Iyer V, Newton-Bishop JA, Timothy Bishop D, Holland EA, Mann GJ, Singh T, Daly MJ, Tsao H. Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing. J Natl Cancer Inst. 2017 Dec 1;109(12). PMCID: PMC5939858
Haugh AM, Njauw CN, Bubley JA, Verzì AE, Zhang B, Kudalkar E, VandenBoom T, Walton K, Swick BL, Kumar R, Rana HQ, Cochrane S, McCormick SR, Shea CR, Tsao H, Gerami P. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature. JAMA Dermatol. 2017 Oct 1;153(10):999-1006. PMCID: PMC5710339
Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017 Jun 1;123(S11):2104-2117. Review.
Roh MR, Eliades P, Gupta S, Grant-Kels JM, Tsao H. Cutaneous melanoma in women. Int J Womens Dermatol. 2017 Mar; 3(1 Suppl): S11–S15. PMCID: PMC5419022
Roh MR, Park KH, Chung KY, Shin SJ, Rha SY, Tsao H. Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. Am J Cancer Res. 2017 Jan 1;7(1):134-138. PMCID: PMC5250687
Torres A, Tsao H. Commentary: American Academy of Dermatology free skin cancer screening: 30 years of value. J Am Acad Dermatol. 2017 Jan;76(1):181-182. No abstract available.
Tsao H. Introduction to JID's Landmarks in the Molecular Revolution. J Invest Dermatol. 2017 May;137(5):996. No abstract available.
Tsao H, Fukunaga-Kalabis M, Herlyn M. Recent Advances in Melanoma and Melanocyte Biology. J Invest Dermatol. 2017 Mar;137(3):557-560. Review. No abstract available.
Eliades P, Miller DM, Miao B, Kumar R, Taylor M, Buch S, Srinivasa SP, Flaherty KT, Tsao H. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 Jul 2;17(7):778-84.
Eliades P, Tsao H. New Insights into the Molecular Distinction of Dysplastic Nevi and Common Melanocytic Nevi-Highlighting the Keratinocyte-Melanocyte Relationship. J Invest Dermatol. 2016 Oct;136(10):1933-5.
Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. Tahe state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16.
Ratushny V, Kraft S, Moschella SL, Duncan LM, Lawrence DP, Tsao H. A Symmetric Eczematous Eruption Harboring Thousands of Melanocytic Lesions. JAMA Dermatol. 2016 Sep 1;152(9):1021-4.
Roh MR, Gupta S, Park KH, Chung KY, Lauss M, Flaherty KT, Jönsson G, Rha SY, Tsao H. Promoter Methylation of PTEN is a Significant Prognostic Factor in Melanoma Survival. J Invest Dermatol. 2016 May;136(5):1002-11.
Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling. J Am Acad Dermatol. 2016 Mar;74(3):411-20. Review. PMCID: PMC4761106
Soura E, Stratigos AJ, Tsao H. Reply to: "The absence of multiple atypical nevi in germline CDKN2A mutations". J Am Acad Dermatol. 2016 Oct;75(4):e159. No abstract available.
Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol. 2016 Mar;74(3):395-407. Review. PMCID: PMC4761105
Tsao H, Weinstock MA. Visual Inspection and the US Preventive Services Task Force Recommendation on Skin Cancer Screening. JAMA. 2016 Jul 26;316(4):398-400. No abstract available.
Wang H, Osseiran S, Igras V, Nichols AJ, Roider EM, Pruessner J, Tsao H, Fisher DE, Evans CL. In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. Sci Rep. 2016 Nov 28;6:37986. PMCID: PMC5125099
Wu JW, Turcotte R, Alt C, Runnels JM, Tsao H, Lin CP. Defining Clonal Color in Fluorescent Multi-Clonal Tracking. Sci Rep. 2016 Apr 13;6:24303. PMCID: PMC4829845
American Academy of Dermatology Ad Hoc Task Force for the ABCDEs of Melanoma, Tsao H, Olazagasti JM, Cordoro KM, Brewer JD, Taylor SC, Bordeaux JS, Chren MM, Sober AJ, Tegeler C, Bhushan R, Begolka WS. Early detection of melanoma: reviewing the ABCDEs. J Am Acad Dermatol. 2015 Apr;72(4):717-23.
Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, Rosengren F, Werner-Hartman L, Törngren T, Kvist A, Fredlund E, Bendahl PO, Jirström K, Lundgren L, Howlin J, Borg Å, Gruvberger-Saal SK, Saal LH, Nielsen K, Ringnér M, Tsao H, Olsson H, Ingvar C, Staaf J, Jönsson G. Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget. 2015 May 20;6(14):12297-309. PMCID: PMC4494939
Gerami P, Tsao H. Concerns About Presence of a Wild-Type BAP1 Allele in Absence of Nuclear Protein Expression-Reply. JAMA Dermatol. 2015 Nov 1;151(11):1266.
Gerami P, Yélamos O, Lee CY, Obregon R, Yazdan P, Sholl LM, Guitart GE, Njauw CN, Tsao H. Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation. JAMA Dermatol. 2015 Nov 1;151(11):1235-9.
Gupta S, Artomov M, Goggins W, Daly M, Tsao H. Gender Disparity and Mutation Burden in Metastatic Melanoma. J Natl Cancer Inst. 2015 Aug 20;107(11). PMCID: PMC4643631
Ho AW, Tsao H. Targeted Therapies in Melanoma: Translational Research at Its Finest. J Invest Dermatol. 2015 Aug;135(8):1929-33. PMCID: PMC4505740
Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw CN, Miao B, Frederick DT, Wargo JA, Flaherty KT, Jönsson G, Tsao H. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol. 2015 Jul;135(7):1863-72. PMCID: PMC4466007
Kumar R, Taylor M, Miao B, Ji Z, Njauw JC, Jönsson G, Frederick DT, Tsao H. BAP1 Has a Survival Role in Cutaneous Melanoma. J Invest Dermatol. 2015 Apr;135(4):1089-97. PMCID: PMC4366338
Lin WM, Luo S, Muzikansky A, Lobo AZ, Tanabe KK, Sober AJ, Benedict Cosimi A, Tsao H, Duncan LM. Outcome of patients with de novo versus nevus-associated melanoma. J Am Acad Dermatol. 2015 Jan;72(1):54-8.
Luo S, Lobo AZ, Tanabe KK, Muzikansky A, Durazzo T, Sober A, Tsao H, Cosimi AB, Lawrence DP, Duncan LM. Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. JAMA Surg. 2015 May;150(5):465-72.
Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H. EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. Cancer Discov. 2015 Mar;5(3):274-87. PMCID: PMC4355085
Paraiso KH, Thakur MD, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype. Cancer Discov. 2015 Mar;5(3):264-73. PMCID: PMC4355213
Roh MR, Eliades P, Gupta S, Tsao H. Cutaneous Melanoma in Women. Int J Womens Dermatol. 2015 Feb 1;1(1):21-25. PMCID: PMC4380274
Roh MR, Eliades P, Gupta S, Tsao H. Genetics of melanocytic nevi. Pigment Cell Melanoma Res. 2015 Nov;28(6):661-72. Review. PMCID: PMC4609613
Tsao H, Begolka WS; American Academy of Dermatology Ad Hoc Task Force for the ABCDEs of Melanoma. Reply to: "The ABCDs of melanoma-A complicated morphologic message not intended for the general public". J Am Acad Dermatol. 2015 Aug;73(2):e61.
Tsao H, Olazagasti JM, Cordoro KM, Brewer JD, Taylor SC, Bordeaux JS, Chren MM, Sober AJ, Tegeler C, Bhushan R, Begolka WS. Early detection of melanoma: Reviewing the ABCDEs. J Am Acad Dermatol. 2015 Apr;72(4):717-23.
Wadt KA, Aoude LG, Johansson P, Solinas A, Pritchard A, Crainic O, Andersen MT, Kiilgaard JF, Heegaard S, Sunde L, Federspiel B, Madore J, Thompson JF, McCarthy SW, Goodwin A, Tsao H, Jönsson G, Busam K, Gupta R, Trent JM, Gerdes AM, Brown KM, Scolyer RA, Hayward NK. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet. 2015 Sep;88(3):267-72.
Hawryluk EB, Tsao H. Melanoma: Clinical Features and Genomic Insights. Cold Spring Harb Perspect Med. 2014 Sep 2;4(9):a015388.
Luo S, Tsao H. Epidermal, sebaceous, and melanocytic nevoid proliferations are spectrums of mosaic RASopathies. J Invest Dermatol. 2014 Oct;134(10):2493-6.
Marzuka-Alcalá A, Gabree MJ, Tsao H. Melanoma susceptibility genes and risk assessment. Methods Mol Biol. 2014;1102:381-93.
Miller DM, Flaherty KT, Tsao H. Commentary: Molecular testing in melanoma. J Am Acad Dermatol. 2014 May;70(5):863-70.
Miller DM, Flaherty KT, Tsao H. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Semin Cutan Med Surg. 2014 Jun;33(2):60-7.
Redmond RW, Rajadurai A, Udayakumar D, Sviderskaya EV, Tsao H. Melanocytes Are Selectively Vulnerable to UVA-Mediated Bystander Oxidative Signaling. J Invest Dermatol. 2014 Apr;134(4):1083-90. PMCID: PMC3961534
Strazzula L, Vedak P, Hoang MP, Sober A, Tsao H, Kroshinsky D. The utility of re-excising mildly and moderately dysplastic nevi: A retrospective analysis. J Am Acad Dermatol. 2014 Dec;71(6):1071-6.
Yonekawa Y, Kim IK, Gragoudas ES, Njauw CN, Tsao H, Jakobiec FA, Stacy RC. Aggressive skull base metastasis from uveal melanoma: a clinicopathologic study. Eur J Ophthalmol. 2014 Jul 24;24(5):811-3.
Bis S, Tsao H. Melanoma genetics: the other side. Clin Dermatol. 2013 Mar;31(2):148-55.
Chen ST, Geller AC, Tsao H. Update on the Epidemiology of Melanoma. Curr Dermatol Rep. 2013 Mar 1;2(1):24-34. PMCID: PMC3619431
Chen YE, Tsao H. The skin microbiome: Current perspectives and future challenges. J Am Acad Dermatol. 2013 Jul;69(1):143-55. PMCID: PMC3686918
Hung T, Piris A, Lobo A, Mihm MC Jr, Sober AJ, Tsao H, Tanabe KK, Duncan LM. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol. 2013 Jan;44(1):87-94.
Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcalá A, Chen YE, Njauw CN, Flaherty K, Jönsson G, Tsao H. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res. 2013 Aug 15;19(16):4383-91. PMCID: PMC3777641.
Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricalà C, Dalle S, Duval-Modeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, Martin-Denavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ, Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA, Goldstein AM, Akslen LA, Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet. 2013 Apr;50(4):264-70. PMCID:PMC3607098
Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma. Mol Cancer Ther. 2013 Jul;12(7):1171-9.
Harbst K, Staaf J, Lauss M, Karlsson A, Masback A, Johansson I, Bendahl PO, Vallon-Christersson J, Torngren T, Ekedahl H, Geisler J, Hoglund M, Ringner M, Lundgren L, Jirstrom K, Olsson H, Ingvar C, Borg A, Tsao H, Jonsson GB. Molecular Profiling Reveals Low- And High-Grade Forms of Primary Melanoma. Clin Cancer Res. 2012 Aug 1;18(15):4026-36. PMCID:PMC3467105
Hawryluk EB, Sober AJ, Piris A, Nazarian RM, Hoang MP, Tsao H, Mihm MC Jr, Duncan LM. Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol. 2012 Oct;67(4):727-35.
Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med. 2012 Jan;18(1):27-35.
Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H. p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition. J Invest Dermatol. 2012 Feb;132(2):356-64.
Lobo AZ, Tanabe KK, Luo S, Muzikansky A, Sober AJ, Tsao H, Cosimi AB, Duncan LM. The distribution of microscopic melanoma metastases in sentinel lymph nodes: implications for pathology protocols. Am J Surg Pathol. 2012 Dec;36(12):1841-8.
Nardi V, Song YC, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan A, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 1;18(5):1227-36.
Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: New Insights and New Therapies. J Invest Dermatol. 2012 Mar;132(3 Pt 2):854-63.
Nikolaou V, Stratigos AJ, Tsao H. Hereditary nonmelanoma skin cancer. Semin Cutan Med Surg. 2012 Dec;31(4):204-10.
Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, Deangelis MM, Gragoudas E, Duncan LM, Tsao H. Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families. PLoS One. 2012;7(4):e35295. PMCID: PMC3335872
Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012 Jun 1;26(11):1131-55. Review. PMCID: PMC3371404
Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. EphA2 is a critical oncogene in melanoma. Oncogene. 2011 Dec 15;30(50):4921-9. PMCID: PMC3175290
Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, Tsao H, Barbosa VH, Chuang TY, Duvic M, Ho VC, Sober AJ, Beutner KR, Bhushan R, Smith Begolka W; American Academy of Dermatology. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol. 2011 Nov;65(5):1032-47.
Chatzinasiou F, Lill CM, Kypreou K, Stefanaki I, Nicolaou V, Spyrou G, Evangelou E, Roehr JT, Kodela E, Katsambas A, Tsao H, Ioannidis JP, Bertram L, Stratigos AJ. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst. 2011 Aug 17;103(16):1227-35. Review.
Enzler T, Sano Y, Choo MK, Cottam HB, Karin M, Tsao H, Park JM. Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov. 2011 Nov;1(6):496-507. PMCID:PMC3290412
Lang JM, Shennan M, Njauw JC, Luo S, Bishop JN, Harland M, Hayward NK, Tucker MA, Goldstein AM, Landi MT, Puig S, Gruis NA, Bergman W, Bianchi-Scarra G, Ghiorzo P, Hogg D, Tsao H. A Novel Flexible Multiplex Bead-based Assay for Detecting Germline CDKN2A and CDK4 Variants in Melanoma-Prone Kindreds. J Invest Dermatol. 2011 Feb;131(2):480-6. PMCID: PMC3045700
Lipworth AD, Park JM, Trefrey BL, Rubin KM, Geller AC, Sober AJ, Tsao H. Urgent access to a specialty care melanoma clinic is associated with a higher rate of melanoma detection. J Am Acad Dermatol. 2011 Jun;64(6):1060-7.
Luo S, Chaplin AC, Langley RG, Njauw CN, Duncan LM, Miller RA, Tsao H. Agminated Segmental Nevi Demonstrating Intranevic Concordance of BRAF Status. J Invest Dermatol. 2011 Mar;131(3):788-90. PMCID: PMC3173815
Luo S, Sepehr A, Tsao H. Spitz nevi and other Spitzoid lesions part I. Natural history and management. J Am Acad Dermatol. 2011 Dec;65(6):1073-84. PMCID:PMC3217183
Luo S, Sepehr A, Tsao H. Spitz nevi and other Spitzoid lesions part II. Background and diagnoses. J Am Acad Dermatol. 2011 Dec;65(6):1087-92. PMCID:PMC3217195
Sepehr A, Chao E, Trefrey B, Blackford A, Duncan LM, Flotte TJ, Sober A, Mihm MC Jr, Tsao H. Long-term outcome of Spitz-type melanocytic tumors. Arch Dermatol. 2011 Oct;147(10):1173-9.
Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. Epha2 is a Critical Oncogene in Melanoma. Oncogene. 2011 December 15; 30(50): 4921–4929. PMCID: PMC3175290
Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature. 2011 Nov 13;480(7375):99-103. PMCID: PMC3266855
Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 1;70(13):5213-9.
Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, Avril MF, Azizi E, van Belle P, Bergman W, Bianchi-Scarrà G, Bressac-de Paillerets B, Calista D, Carrera C, Hansson J, Harland M, Hogg D, Höiom V, Holland EA, Ingvar C, Landi MT, Lang JM, Mackie RM, Mann GJ, Ming ME, Njauw CJ, Olsson H, Palmer J, Pastorino L, Puig S, Randerson-Moor J, Stark M, Tsao H, Tucker MA, van der Velden P, Yang XR, Gruis N; Melanoma Genetics Consortium. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 2010 Oct 20;102(20):1568-83.
Feramisco JD, Tsao H, Siegel DH. Genetics for the practicing dermatologist. Semin Cutan Med Surg. 2010 Jun;29(2):127-36. Review.
Ji Z, Flaherty KT, Tsao H. Molecular therapeutic approaches to melanoma. Mol Aspects Med. 2010 Apr;31(2):194-204. Epub 2010 Feb 20. Review.
Ko JM, Velez NF, Tsao H. Pathways to melanoma. Semin Cutan Med Surg. 2010 Dec;29(4):210-7.
Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009 Oct;61(4):677.e1-14. PMCID: PMC3307795
Miller AJ, Tsao H. New Insights into Pigmentary Pathways and Skin Cancer. Br J Dermatol. 2010 Jan;162(1):22-8.
Sober AJ, Tsao H. Martin C. Mihm, Jr and the history of the Pigmented Lesion Clinic at the Massachusetts General Hospital. J Cutan Pathol. 2010 Apr;37 Suppl 1:8-11. No abstract available.
Tsao H, Tanabe KK, Lawrence DP, Piris A. Case records of the Massachusetts General Hospital. Case 30-2010. A 15-year-old boy with a recurrent skin lesion. N Engl J Med. 2010 Sep 30;363(14):1352-60. No abstract available.
Udayakumar D, Mahato B, Gabree M, Tsao H. Genetic determinants of cutaneous melanoma predisposition. Semin Cutan Med Surg. 2010 Sep;29(3):190-5.
Udayakumar D, Tsao H. Moderate- to low-risk variant alleles of cutaneous malignancies and nevi: lessons from genome-wide association studies. Genome Med. 2009; 1(10): 95. PMCID: PMC2784308
Wang W, Niendorf KB, Patel D, Blackford A, Marroni F, Sober AJ, Parmigiani G, Tsao H. Personalized Prediction of Germline CDKN2A Mutations and Cancer Risk in Hereditary Melanoma. Cancer Res. 2010 Jan 15;70(2):552-9. PMCID: PMC2947347
Feramisco JD, Sadreyev RI, Murray ML, Grishin NV, Tsao H. Phenotypic and genotypic analyses of genetic skin disease through the Online Mendelian Inheritance in Man (OMIM) database. J Invest Dermatol. 2009 Nov;129(11):2628-36.
Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009 Oct;61(4):677.e1-14. Review.
Nelson AA, Tsao H. Melanoma and genetics. Clin Dermatol 2009 Jan-Feb;27(1):46-52. Review.
Park JM, Tsao H, Tsao S. Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations. J Am Acad Dermatol. 2009 Jul;61(1):88-93. Review.
Sadreyev RI, Feramisco JD, Tsao H, Grishin NV. Phenotypic categorization of genetic skin diseases reveals new relations between phenotypes, genes and pathways. Bioinformatics. 2009 Nov 15;25(22):2891-6. PMCID: PMC2773259
Udayakumar D, Tsao H. Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin North Am. 2009 Jun;23(3):415-29, vii. Review.
Udayakumar D, Tsao H. Moderate- to low-risk variant alleles of cutaneous malignancies and nevi: lessons from genome-wide association studies. Genome Med. 2009 Oct 27;1(10):95.
Yang G, Thieu K, Tsai KY, Piris A, Udayakumar D, Njauw CN, Ramoni MF, Tsao H. Dynamic Gene Expression Analysis Links Melanocyte Growth Arrest with Nevogenesis. Cancer Res. 2009 Dec 1;69(23):9029-37.
Feramisco JD, Casey RL, Tsao H. Recent updates on genetics: teaching old dogmas new tricks. Pediatr Dermatol 2008;25(1):99-108. Review
Friedman RJ, Gutkowicz-Krusin D, Farber MJ, Warycha M, Schneider-Kels L, Papastathis N, Mihm MC Jr, Googe P, King R, Prieto VG, Kopf AW, Polsky D, Rabinovitz H, Oliviero M, Cognetta A, Rigel DS, Marghoob A, Rivers J, Johr R, Grant-Kels JM, Tsao H. The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol 2008 Apr;144(4):476-82.
Harland M, Goldstein AM, Kukalizch K, Taylor C, Hogg D, Puig S, Badenas C, Gruis N, Ter Huurne J, Bergman W, Hayward NK, Stark M, Tsao H, Tucker MA, Landi MT, Scarra GB, Ghiorzo P, Kanetsky PA, Elder D, Mann GJ, Holland EA, Bishop DT, Newton Bishop J; members of GenoMEL, the Melanoma Genetics Consortium. A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer 2008 Jun;44(9):1269-74. PMCID: PMC2494985
Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from thebenchside to the bedside. J Invest Dermatol 2008;128(11):2575-95.
Park JM, Tsao H, Tsao S. Combined use of intense pulsed light and Q-switched ruby laser for complex dyspigmentation among asian patients. Lasers Surg Med 2008;40(2):128-33.
Somoano B, Tsao H. Genodermatoses with cutaneous tumors and internal malignancies. Dermatol Clin 2008;26(1):69-87.
Sun BK, Tsao H. X-Chromosome inactivation and skin disease. J Invest Dermatol 2008 Dec;128(12):2753-9. Review.
Zhang G, Njauw CN, Park JM, Naruse C, Asano M, Tsao H. EphA2 is an essential mediator of UV radiation-induced apoptosis. Cancer Res 2008;68(6):1691-6.
Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E,Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Cannon-Albright LA, Chaudru V,Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis N, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang JM, Leachman S, Mackie RM, Magnusson V, Mann G, Newton-Bishop J, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, Study Group LM, Genomel MG. Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007 Feb;44(2):99-106. PMCID: PMC2598064
Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 2007 Feb 12;28(6):578-88.
Jarell AD, Lawrende D, Tsao H. The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. [Review]. Biologics: Targ Thera 2007;1(4):407-414. PMCID: PMC2721285
Lang J, Hayward N, Goldgar D, Tsao H, Hogg D, Palmer J, Stark M, Tobias ES, MacKie R. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry. Genes Chromosomes Cancer 2007;46(3):277-87.
McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007 Dec 11;104(50):19936-41. PMCID: PMC2148401
Tsai KY, Tsao H. Primer on the human genome. J Amer Acad Derm 2007 May; 56(5):719-35.
Tsao H, Florez JC. Introduction to genetic association studies. [Editorial] JID 2007;127:2283-87.
Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122(2):337-41.
Tsao H, Tucker MA, Whitaker L, Yakobson E. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007 Feb;44(2):99-106.
Yang G, Curley D, Bosenberg MW, Tsao H. Loss of xeroderma pigmentosum C (xpc) enhances melanoma photocarcinogenesis in ink4a-arf-deficient mice. Cancer Res 2007;67(12):5649-57.
Goggins W, Daniels GH, Tsao H. Elevation of thyroid cancer risk among cutaneous melanoma survivors. Int J Cancer 2006 Jan 1;118(1):185-8.
Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D,Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006 Oct 15;66(20):9818-28.
Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006;12(7 Pt 2):2301s-2307s. [Review].
Niendorf KB, Goggins W, Yang G, Tsai KY, Shennan M, Bell DW, Sober AJ, Hogg D, Tsao H. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet 2006 Jun;43(6):501-6.
Niendorf KB, Tsao H. Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 2006 Jan-Feb;19(1):1-8.
Stratigos AJ, Yang G, Dimisianos R, Nicolaou V, Stefanaki I, Katsambas AD, Tsao H. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma. J Invest Dermatol 2006 Feb;126(2):399-401.
Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H. Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. J Invest Dermatol 2006 Nov;126(11):2490-506.
Somoano B, Niendorf KB, Tsao H. Hereditary cancer syndromes of the skin. Clin Dermatol 2005;23(1):85-106.
Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 2005;125:1242-51.
Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer 2004;111(5):792-4.
Tsai KY, Tsao H. The genetics of skin cancer. Am J Med Genet 2004;131C(1):82-92.
Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351(10):998-1012.
Tsao H, Feldman M, Fullerton JE, Sober AJ, Rosenthal D, Goggins W. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 2004;140(1):67-70.
Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122(2):337-41. PMCID: PMC2586668
Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol 2004;51(5):803-8.
Tsao H, Sober AJ, Niendorf KB, Zembowicz A. Case 6-2004: a 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma. N Engl J Med 2004;350(9):924-32.
Yang G, Niendorf KB, Tsao H. A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred. J Invest Dermatol 2004;123(3):574-5.
Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003;139(12):1620-1624.
Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003; 97(3):639-643.
Tsao H, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and utaneous melanoma. J Am Acad Dermatol 2003; 49(5):865-872.
Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003; 139(3):282-288.
Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H, De Luca M, Catricala C, O'Toole KM. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002; 22(14):5157-5172. PMCID: PMC139780
Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002; 138(6):799-802.
Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer 2001 Feb 15;91(4):874-80.
Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000 Sep;136(9):1118-22.
